BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72-79. [PMID: 19065670 DOI: 10.1002/hep.22658] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Vermehren J, Kau A, Zeuzem S. Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. Curr Hepatitis Rep 2010;9:53-9. [DOI: 10.1007/s11901-010-0036-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol. 2010;52:147-149. [PMID: 20006400 DOI: 10.1016/j.jhep.2009.10.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
3 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study. Dig Dis Sci 2014;59:168-73. [DOI: 10.1007/s10620-013-2940-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
5 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
6 Boyd A, Lacombe K. More Long-term Assessment of Transient Elastography Is Needed for HIV/Hepatitis B Virus-Coinfected Patients Undergoing Treatment With Tenofovir. Clin Infect Dis 2016;62:128-30. [PMID: 26338780 DOI: 10.1093/cid/civ767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
8 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
9 Zhao P, Liu W, Zhao J, Guan Q. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. Virol J 2011;8:75. [PMID: 21342505 DOI: 10.1186/1743-422X-8-75] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
11 Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation. 2014;97 Suppl 8:S53-S59. [PMID: 24849836 DOI: 10.1097/01.tp.0000446278.43804.f9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
12 Lu HY, Zhuang LW, Yu YY, Si CW. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2010;17 Suppl 1:59-65. [PMID: 20586935 DOI: 10.1111/j.1365-2893.2010.01272.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
14 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
15 Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol 2017;8:621. [PMID: 28611778 DOI: 10.3389/fimmu.2017.00621] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
16 Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144-151. [PMID: 23359454 DOI: 10.1002/phar.1188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
17 Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279. [PMID: 23390496 DOI: 10.1371/journal.pone.0054279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
18 Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat 2011;2011:524027. [PMID: 22114737 DOI: 10.1155/2011/524027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Lee GH, Aung MO, Dan YY, Lee YM, Mak B, Low HC, Lim K, Thwin MA, Tan PS, Lim SG. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol. 2013;85:26-33. [PMID: 23023992 DOI: 10.1002/jmv.23392] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
20 Maklad S, Doss W, El Din SS, Hassan K, Zeid AA. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. Arab J Gastroenterol. 2014;15:1-5. [PMID: 24630505 DOI: 10.1016/j.ajg.2014.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wiens A, Lenzi L, Venson R, Pedroso ML, Correr CJ, Pontarolo R. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis. 2013;17:418-426. [PMID: 23849851 DOI: 10.1016/j.bjid.2012.12.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
22 Li H, Wang H, Peng C, Zheng X, Liu J, Weng ZH, Yang DL. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. J Huazhong Univ Sci Technolog Med Sci 2017;37:547-55. [PMID: 28786051 DOI: 10.1007/s11596-017-1771-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
23 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
24 Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Lee DH, Kim N, Hwang JH, Park YS, Lee SH. [Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]. Korean J Hepatol 2010;16:57-65. [PMID: 20375643 DOI: 10.3350/kjhep.2010.16.1.57] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily. Journal of Clinical Gastroenterology 2013;47:461-5. [DOI: 10.1097/mcg.0b013e318266fd31] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Shin SK, Kim JH, Park H, Kwon OS, Lee HJ, Yeon JE, Byun KS, Suh SJ, Yim HJ, Kim YS. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. J Gastroenterol Hepatol. 2015;30:1775-1781. [PMID: 26095700 DOI: 10.1111/jgh.13020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014;20:401-13. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Reference Citation Analysis]
29 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326-1335. [PMID: 22506552 DOI: 10.1111/j.1365-2036.2012.05098.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
31 Lai CL, Yuen MF. The saga of entecavir. Hepatol Int 2009;3:421-4. [PMID: 19669247 DOI: 10.1007/s12072-009-9138-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026. [PMID: 21127728 DOI: 10.1155/2010/143026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
33 Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23:935-940. [PMID: 28668466 DOI: 10.1016/j.cmi.2017.06.023] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
34 Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. Journal of Hepatology 2012;57:885-96. [DOI: 10.1016/j.jhep.2012.03.036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
35 Khungar V, Han SH. A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010;9:75-90. [PMID: 20461127 DOI: 10.1007/s11901-010-0039-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
36 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
37 Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28:855-860. [PMID: 23278507 DOI: 10.1111/jgh.12108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
38 Con D, Goodwin T, Majeed A, Roberts S, Kemp W. Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis. J Viral Hepat 2021;28:40-50. [PMID: 32893921 DOI: 10.1111/jvh.13400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
39 Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, Tan DM, Ren H, Tang H, Cohen D, Llamoso C. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20:811-20. [PMID: 23876210 DOI: 10.1111/jvh.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
40 Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
41 Ohishi W, Chayama K. Current treatment for chronic hepatitis B in Japan. Clin J Gastroenterol 2009;2:325-30. [DOI: 10.1007/s12328-009-0100-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
42 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Liu A, Ha NB, Lin B, Yip B, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Garcia G, Nguyen MH. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. Eur J Gastroenterol Hepatol. 2013;25:338-343. [PMID: 23169311 DOI: 10.1097/meg.0b013e32835b3677] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
44 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
45 Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512-520. [PMID: 20102511 DOI: 10.1111/j.1478-3231.2009.02198.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
46 Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis. 2011;32:1122-1132. [PMID: 21665892 DOI: 10.1093/carcin/bgr108] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
47 Chan HL, Wong VW. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 540-63. [DOI: 10.1016/b978-1-4377-0881-3.00030-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
48 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
49 Zhuang Y, Li X, Li X, Xu H, Ye H, Sun D, Liu X, Ren G. Association of KIR Genotypes and Haplotypes in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir. Immunol Invest 2019;48:333-44. [PMID: 30325691 DOI: 10.1080/08820139.2018.1529791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Almeida AM, Ribeiro AQ, Pádua CA, Brandão CM, Andrade EI, Cherchiglia ML, Carmo RA, Acurcio Fde A. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop 2010;43:440-51. [PMID: 20802947 DOI: 10.1590/s0037-86822010000400021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat. 2012;19:e41-e47. [PMID: 22239525 DOI: 10.1111/j.1365-2893.2011.01509.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
52 Sacco R. Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med 2012;4:39-47. [PMID: 24696620 DOI: 10.2147/HMER.S16136] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Pan CQ, Tong M, Kowdley KV, Hu K, Chang T, Lai C, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:1047-1050.e1. [DOI: 10.1016/j.cgh.2012.03.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
54 Zhao FJ, Tang H, Zhang QH, Yang J, Davey AK, Wang JP. Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012;881-882:119-25. [PMID: 22197609 DOI: 10.1016/j.jchromb.2011.12.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
55 Li X, Li F, Zhang Y, Kang Y, Yu J, Yang F, Liu H, Qin Y, Huang Y, Mao R, Zhang J. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. Biochem Biophys Res Commun 2015;464:1185-91. [PMID: 26212437 DOI: 10.1016/j.bbrc.2015.07.101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Wu CS, Zhao Q, Zhang J, Wang JW, Qian Y, Fan YC, Wang K. Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e13904. [PMID: 30593207 DOI: 10.1097/MD.0000000000013904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
58 Koziel MJ, Thio CL. Hepatitis B Virus and Hepatitis Delta Virus. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2059-86. [DOI: 10.1016/b978-0-443-06839-3.00146-6] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
59 Lampertico P, Viganò M, Colombo M. Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. Curr Hepatitis Rep 2012;11:90-4. [DOI: 10.1007/s11901-012-0127-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283-1292. [PMID: 24382690 DOI: 10.1002/hep.26885] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
61 Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther 2014;3:191-202. [PMID: 25228496 DOI: 10.1007/s40121-014-0039-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton). 2010;15:137-145. [PMID: 20470270 DOI: 10.1111/j.1440-1797.2009.01268.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
63 Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143:619-28.e1. [PMID: 22643350 DOI: 10.1053/j.gastro.2012.05.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 10.2] [Reference Citation Analysis]
64 Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. J Med Virol. 2012;84:424-430. [PMID: 22246827 DOI: 10.1002/jmv.23229] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
65 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
66 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91-100. [PMID: 21503940 DOI: 10.1002/hep.24361] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
67 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
68 Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040. [PMID: 21682661 DOI: 10.1517/14656566.2011.590474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
69 Lok AS. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J Hepatol 2009;51:416-8. [PMID: 19410323 DOI: 10.1016/j.jhep.2009.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
70 Hynicka LM, Yunker N, Patel PH. A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B. Ann Pharmacother 2010;44:1271-86. [DOI: 10.1345/aph.1m590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
71 Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218-1229. [PMID: 20600036 DOI: 10.1053/j.gastro.2010.06.042] [Cited by in Crossref: 167] [Cited by in F6Publishing: 158] [Article Influence: 13.9] [Reference Citation Analysis]
72 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213-1218. [PMID: 24179497 DOI: 10.3892/ol.2013.1578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
73 Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2009;7:1053-62. [PMID: 19883325 DOI: 10.1586/eri.09.75] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
74 Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, Hong SK, Joo MK, Yeon JE, Park JJ, Kim JS, Bak Y, Byun KS. Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir. Journal of Clinical Gastroenterology 2010;44:653-7. [DOI: 10.1097/mcg.0b013e3181d52946] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
75 Govan L, Wu O, Xin Y, Hutchinson SJ, Hawkins N. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. European Journal of Gastroenterology & Hepatology 2015;27:882-94. [DOI: 10.1097/meg.0000000000000376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol 2017;17:39. [PMID: 28279168 DOI: 10.1186/s12876-017-0596-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
77 Yip B, Chaung K, Wong CR, Trinh HN, Nguyen HA, Ahmed A, Cheung R, Nguyen MH. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci. 2012;57:3011-3016. [PMID: 23010744 DOI: 10.1007/s10620-012-2402-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
78 Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020;18:823-34. [PMID: 32329638 DOI: 10.1080/14787210.2020.1760843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Wang Y, Liu S, Chen Y, Zheng S, Zhou L, Lu F, Duan Z. Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. Int J Med Sci 2015;12:416-22. [PMID: 26005376 DOI: 10.7150/ijms.11687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
81 Zheng M, Shi K, Dai Z, Ye C, Chen Y. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clinical Therapeutics 2010;32:649-58. [DOI: 10.1016/j.clinthera.2010.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
82 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf. 2012;11:361-368. [PMID: 22233350 DOI: 10.1517/14740338.2012.653340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
83 Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013;19:887-895. [PMID: 23788462 DOI: 10.1002/lt.23690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
84 Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010;54:1242-1247. [PMID: 20028815 DOI: 10.1128/aac.01163-09] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
85 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
86 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
88 Kimberlin DW. Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1551-1567.e6. [DOI: 10.1016/b978-0-323-40181-4.00295-4] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
90 Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68:2154-2163. [PMID: 23620466 DOI: 10.1093/jac/dkt147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
91 Zhao SH, Liu EQ, Cheng DX, Li YF, Wang YL, Chen YL, Sun WT, Yan XC, Dang SS. Comparison of entecavir and adefovir for the treatment of chronic hepatitis B. Braz J Infect Dis 2012;16:366-72. [PMID: 22846126 DOI: 10.1016/j.bjid.2012.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98865. [PMID: 24905092 DOI: 10.1371/journal.pone.0098865] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
93 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
94 Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology 2016;50:169-74. [DOI: 10.1097/mcg.0000000000000345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
95 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
96 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
97 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547. [PMID: 23389810 DOI: 10.1002/hep.26301] [Cited by in Crossref: 295] [Cited by in F6Publishing: 283] [Article Influence: 32.8] [Reference Citation Analysis]
98 Petersen J, Buti M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol. 2012;6:683-693; quiz 694. [PMID: 23237254 DOI: 10.1586/egh.12.52] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
99 Jonas MM, Chang MH, Sokal E, Schwarz KB, Kelly D, Kim KM, Ling SC, Rosenthal P, Oraseanu D, Reynolds L, Thiry A, Ackerman P. Randomized, controlled trial of entecavir vs placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology. 2016;63:377-387. [PMID: 26223345 DOI: 10.1002/hep.28015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
100 Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893. [PMID: 20683932 DOI: 10.1002/hep.23785] [Cited by in Crossref: 627] [Cited by in F6Publishing: 596] [Article Influence: 52.3] [Reference Citation Analysis]
101 Lee MH, Lim S, Jeon SJ, Kang CJ, Cho YJ, Kim SS, Lee D, Cheong JY, Cho SW. Clinical efficacy of entecavir therapy and factors associated with treatment response in naïve chronic hepatitis B patients. Korean J Hepatol 2009;15:446. [DOI: 10.3350/kjhep.2009.15.4.446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
102 Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, Zhou WP, Wu MC. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol. 2013;20:1482-1490. [PMID: 23247982 DOI: 10.1245/s10434-012-2803-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
103 Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 [PMID: 25339803 DOI: 10.3748/wjg.v20.i39.14142] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
104 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
105 Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393. [PMID: 21824397 DOI: 10.1186/1743-422x-8-393] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
106 Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepat 2010;17 Suppl 1:51-8. [PMID: 20586934 DOI: 10.1111/j.1365-2893.2010.01271.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
107 Wei Q, Tian H, Luo H, Zhang Y, Deng Y, Yao J, Li H, Chen G, Yang Y. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Asian Journal of Surgery 2017;40:453-62. [DOI: 10.1016/j.asjsur.2016.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
108 Heo J, Ahn SH, Kweon YO, Kim BH, Chan HL, Horban A, Wongcharatrawee S, Llamoso C, Lee KS. Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1485-93. [PMID: 25587617 DOI: 10.1111/jgh.12567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117:588-597. [PMID: 29456079 DOI: 10.1016/j.jfma.2017.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
110 Hongthanakorn C, Lok AS. New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am 2010;39:659-80. [PMID: 20951923 DOI: 10.1016/j.gtc.2010.08.012] [Reference Citation Analysis]
111 Rizzetto M. Treatment of hepatitis B virus cirrhosis. Hepat Mon 2012;12:309-11. [PMID: 22783340 DOI: 10.5812/hepatmon.6113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Singh US, Mulamoottil VA, Chu CK. 2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants. Med Res Rev 2018;38:977-1002. [DOI: 10.1002/med.21490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18:e475-e481. [PMID: 21914066 DOI: 10.1111/j.1365-2893.2011.01479.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
114 Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol 2012;12:178. [PMID: 23234302 DOI: 10.1186/1471-230X-12-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]